APA (7th ed.) Citation

Owen, A., Spinks, J., Meehan, A., Robb, T., Hardy, M., Kwasha, D., . . . Reid, C. (2008). A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry.

Chicago Style (17th ed.) Citation

Owen, A., J. Spinks, A. Meehan, T. Robb, M. Hardy, D. Kwasha, J. Wlodarczyk, and Christopher Reid. A New Model to Evaluate the Long-term Cost Effectiveness of Orphan and Highly Specialised Drugs Following Listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry. 2008.

MLA (9th ed.) Citation

Owen, A., et al. A New Model to Evaluate the Long-term Cost Effectiveness of Orphan and Highly Specialised Drugs Following Listing on the Australian Pharmaceutical Benefits Scheme: The Bosentan Patient Registry. 2008.